A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

Psychiatry is often treated as separate to the rest of medicine. It's time to bring psychiatry into the era of precision medicine.

Prader-Willi syndrome is a rare genetic condition that leads to physical and behavioral problems. A common feature of the condition is feeling hungry all the time, and people with Prader-Willi have an ...

Complex regional pain syndrome (CRPS) is a rare but severe neuropathic pain condition that causes intense, long-lasting pain, often following an injury or surgery. Patients frequently report some of ...

Today, Europe stands as a critical region for biotech companies looking to advance medical breakthroughs in specialized fields, including oncology, rare diseases, and cell and gene therapy. In ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

Nature writes the best horror stories – In The New York Times’ recent piece, the return of the screwworm, a flesh‑eating parasite once eradicated from the U.S. Indeed, cattle ranchers are once again ...

For instance, California-based Calidi Biotherapeutics’ oncolytic virus CLD-201 was awarded fast track designation from the U.S. Food and Drug Administration (FDA) three days ago. The fast track ...